P. Schoenfeld Asset Management (PSAM)’s Aspire Biopharma ASBP Stock Holding History

P. Schoenfeld Asset Management (PSAM)’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49	Closed	-$7.72K	–	52
2025 Q4	$7.72K	Hold	49	–	–	﹤0.01%	43
2025 Q3	$12.1K	Buy	+49	New	+$24.5K	﹤0.01%	38
2024 Q1	–	Sell	-111	Closed	-$1.45M	–	56
2023 Q4	$1.45M	Hold	111	–	–	0.34%	38
2023 Q3	$1.44M	Sell	111 -14	-11%	-$180K	0.12%	61
2023 Q2	$1.59M	Buy	+125	New	+$1.57M	0.1%	61

Other funds holding ASBP

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM)'s ASBP Position: Q1 2026 in Review

P. Schoenfeld Asset Management (PSAM) sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 49 shares — an estimated $7.72K sold.

P. Schoenfeld Asset Management (PSAM) first reported a position in ASBP in Q2 2023 and held it in 5 quarters. The position peaked at $1.59M in Q2 2023. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

P. Schoenfeld Asset Management (PSAM) reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
P. Schoenfeld Asset Management (PSAM) sold 49 Aspire Biopharma shares in Q1 2026, an estimated $7.72K.
P. Schoenfeld Asset Management (PSAM) first reported a position in Aspire Biopharma in Q2 2023 and held it in 5 quarters.
P. Schoenfeld Asset Management (PSAM)'s Aspire Biopharma position peaked at $1.59M in Q2 2023.
12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on P. Schoenfeld Asset Management (PSAM)'s 13F filing for Q1 2026, filed 15 May 2026.